Alnylam Pharmaceuticals
ALNY
310 hedge funds and large institutions have $9.02B invested in Alnylam Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 57 funds opening new positions, 123 increasing their positions, 79 reducing their positions, and 39 closing their positions.
88% more call options, than puts
Call options by funds: $106M | Put options by funds: $56.4M
56% more repeat investments, than reductions
Existing positions increased: 123 | Existing positions reduced: 79
46% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 39
6% more funds holding
Funds holding: 293 → 310 (+17)
0.4% less ownership
Funds ownership: 91.48% → 91.08% (-0.4%)
17% less capital invested
Capital invested by funds: $10.9B → $9.02B (-$1.9B)
25% less funds holding in top 10
Funds holding in top 10: 12 → 9 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$216M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$69.4M |
| 3 |
MC
Maverick Capital
Dallas,
Texas
|
+$67.6M |
| 4 |
JP Morgan Chase
New York
|
+$57.3M |
| 5 |
PA
Perceptive Advisors
New York
|
+$56.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$730M |
| 2 |
BlackRock
New York
|
-$103M |
| 3 |
Janus Henderson Group
London,
|
-$39.9M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$35.4M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$28.6M |
ALNY Hedge Fund Activity: Q2 2018 in Review
310 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q2 2018, worth a combined $9.02B — down 17% from $10.9B a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new ALNY positions and 39 closed out — a net gain of 18 holders — while 123 added to existing stakes and 79 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $216M. The largest seller was T. Rowe Price Associates, cutting an estimated $730M.
- 310 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q2 2018, up from 293 in Q1 2018.
- Funds reported $9.02B of Alnylam Pharmaceuticals stock for Q2 2018, down 17% quarter-over-quarter.
- 57 funds opened new Alnylam Pharmaceuticals positions in Q2 2018 and 39 closed out, a net change of +18 holders.
- The largest Alnylam Pharmaceuticals buyer in Q2 2018 was Wellington Management Group, an estimated $216M added.
- The largest Alnylam Pharmaceuticals seller in Q2 2018 was T. Rowe Price Associates, an estimated $730M sold.
Based on aggregated 13F filings for Q2 2018.